Berry DA et al. Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, nodepositive breast cancer: 20-year experience of the CALGB and US Breast Intergroup. Breast Cancer Res Treat 2004;Abstract 29.

Biganzoli L et al. Adjuvant chemotherapy in elderly patients with breast cancer: A survey of the Breast International Group (BIG). Ann Oncol 2004;15(2):207-10. Abstract

Boccardo F et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23(22):5138-47. Abstract

Boccardo F et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003;Abstract 3.

Bonadonna G et al. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and fluorouracil in operable breast cancer. J Clin Oncol 2004;22(9):1614-20. Abstract

Brain EGC et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high-risk node negative (pN0) and limited node positive (pN+≤3) breast cancer (BC) patients (pts): First analysis of toxicity. Proc ASCO 2004;Abstract 617.

Carlson RW et al. Goserelin plus anastrozole for the treatment of premenopausal women with hormone receptor positive, recurrent/ metastatic breast cancer. Breast Cancer Res Treat 2004;Abstract 6052.

Castiglione-Gertsch M et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph nodenegative breast cancer: A randomized trial. J Natl Cancer Inst 2003;95(24):1833-46. Abstract

Citron ML et al. Randomized trial of dosedense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract

Coombes RC et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081- 92. Abstract

Cuzick J, Howell A. Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer. Presentation. ASCO 2005;Abstract 658.

Davidson NE et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188). J Clin Oncol 2005;23(25):5973-82. Abstract

Delozier T et al. Reducing dose density in adjuvant chemotherapy is detrimental in early breast cancer (EBC). A review of 872 adjuvant treatments in Centre François Baclesse. Proc ASCO 2004;Abstract 583.

Dowsett M, on behalf of the ATAC Trialists’ Group. Analysis of time to recurrence in the ATAC (Anastrozole, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003;83(Suppl 1):7;Abstract 4.

Duffy S, on behalf of the ATAC Trialist’s Group. Gynecological adverse events including hysterectomy occur less frequently with anastrozole than with tamoxifen: Data from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial. Proc ASCO 2005;Abstract 723.

Duffy S et al. The ATAC adjuvant breast cancer trial in postmenopausal women: Baseline endometrial subprotocol data. BJOG 2003;110(12):1099-106. Abstract

Duric V et al. Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC). Proc ASCO 2004;Abstract 787.

Evans TR et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An angloceltic cooperative oncology group study. J Clin Oncol 2005;23(13):2988-95. Abstract

Ghani F et al. Confirmation of C9741 intergroup results in a prospectively randomized trial comparing dose-intense chemotherapy with G-CSF support to 3-weekly chemotherapy for adjuvant therapy of nodal-positive (1-3 LN) breast cancer: Longitudinal CA 27.29 results indicate higher decay of minimal residual disease in the dose-dense arm. Proc ASCO 2004;Abstract 805.

Giordano SH et al. Breast cancer treatment guidelines in older women. J Clin Oncol 2005;23(4):783-91. Abstract

Gnant M et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen — Bone density subprotocol results of a randomized multicenter trial (ABCSG-12). Breast Cancer Res Treat 2004;Abstract 6.

Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA17. J Natl Cancer Inst 2005;97(17):1262-71. Abstract

Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract

Henderson IC et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer. J Clin Oncol 2003;21(6):976-83. Abstract

Houghton J et al. Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: Updated data from the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial. Proc ASCO 2005;Abstract 582.

Howell A et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Howell A et al. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer — Updated efficacy results based on a median follow-up of 5 years. Breast Cancer Res Treat 2004;Abstract 1.

Hudis CA, Schmitz N. Dose-dense chemotherapy in breast cancer and lymphoma. Semin Oncol 2004;31(3 Suppl 8):19-26. Abstract

Jakesz R et al. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). Proc ASCO 2005;Abstract 527.

Jakesz R et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 2004;Abstract 2.

Kennecke H et al. 10 year event-free survival (EFS) in postmenopausal women with early stage breast cancer during the second five years after adjuvant tamoxifen. Breast Cancer Res Treat 2004;Abstract 1049.

Levine MN et al; National Cancer Institute of Canada Clinical Trials Group. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005;23(22):5166-70. Abstract

Locker GY et al. The time course of bone fractures observed in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial. Proc ASCO 2003;Abstract 98.

Loesch D et al. A randomized, multicenter phase III trial comparing regimens of doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer. Breast Cancer Res Treat 2004;Abstract 28.

Loprinzi CL, Ravdin PM. Decision-making for patients with resectable breast cancer: Individualized decisions for and by patients and their physicians. JNCCN 2003;1(2):189-96.

Love RR et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 2003;21(3):453-7. Abstract

Love RR et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 2002;20(10):2559-66. Abstract

Lyman GH et al. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol 2003;21(24):4524-31. Abstract

Mamounas EP et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 2005;23(16):3686-96. Abstract

Martin M et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352(22):2302-13. Abstract

Martin M et al. Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): An interim safety analysis of the GEICAM 9805 study. Proc ASCO 2004;Abstract 620.

Martin M et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res Treat 2003;Abstract 43.

Muss HB et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293(9):1073-81. Abstract

Nowak AK et al. Systematic review of taxanecontaining versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 2004;5(6):372-80. Abstract

Perez EA. Effect of letrozole versus placebo on bone mineral density in women completing > 5 years (yrs) of adjuvant tamoxifen: NCIC CT MA.17b. Breast Cancer Res Treat 2004;Abstract 404.

Punglia RS et al. Optimizing adjuvant endocrine therapy in postmenopausal women with earlystage breast cancer: A decision analysis. J Clin Oncol 2005;23(22):5178-87. Abstract

Thewes B et al. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol 2005;6(8):581-8. Abstract

Thürlimann B. BIG 1-98: A prospective randomized double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast 2005;14(Suppl 1):3;S4. No Abstract available

Thürlimann B et al. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Proc ASCO 2005;Abstract 511.

Vogel CL et al. The role of growth factor support following neutropenic events in early stage breast cancer (BC) patients treated with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC): A sub-analysis of BCIRG 001. Proc ASCO 2004;Abstract 677.

Winer EP et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptorpositive breast cancer: Status report 2004. J Clin Oncol 2005;23(3):619-29. Abstract